LV11326B - Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof Download PDF

Info

Publication number
LV11326B
LV11326B LVP-96-85A LV960085A LV11326B LV 11326 B LV11326 B LV 11326B LV 960085 A LV960085 A LV 960085A LV 11326 B LV11326 B LV 11326B
Authority
LV
Latvia
Prior art keywords
acid
compound
temperature
composition
quot
Prior art date
Application number
LVP-96-85A
Other languages
English (en)
Latvian (lv)
Other versions
LV11326A (lv
Inventor
Roger Cherng Fu
De - Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LV11326A publication Critical patent/LV11326A/xx
Publication of LV11326B publication Critical patent/LV11326B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-96-85A 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof LV11326B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15
PCT/US1994/010142 WO1995007902A1 (en) 1993-09-15 1994-09-12 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (2)

Publication Number Publication Date
LV11326A LV11326A (lv) 1996-06-20
LV11326B true LV11326B (en) 1996-10-20

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-85A LV11326B (en) 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Country Status (32)

Country Link
US (2) US5543408A (lt)
EP (1) EP0724581B1 (lt)
JP (1) JP3411038B2 (lt)
KR (1) KR100349772B1 (lt)
CN (1) CN1060770C (lt)
AT (1) ATE173475T1 (lt)
AU (1) AU677435B2 (lt)
BR (1) BR9407469A (lt)
CA (1) CA2171836C (lt)
CZ (1) CZ292423B6 (lt)
DE (1) DE69414720T2 (lt)
DK (1) DK0724581T3 (lt)
ES (1) ES2123831T3 (lt)
FI (1) FI119639B (lt)
HK (1) HK1012624A1 (lt)
HU (1) HU217300B (lt)
IL (1) IL110970A (lt)
LT (1) LT4052B (lt)
LV (1) LV11326B (lt)
MX (1) MXPA94007099A (lt)
NO (1) NO314727B1 (lt)
NZ (1) NZ273801A (lt)
PH (1) PH30685A (lt)
PL (1) PL178522B1 (lt)
RO (2) RO118075B1 (lt)
RU (1) RU2132849C1 (lt)
SG (1) SG55006A1 (lt)
SI (1) SI9420052B (lt)
TW (1) TW370527B (lt)
UA (1) UA49797C2 (lt)
WO (1) WO1995007902A1 (lt)
ZA (1) ZA947088B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (lt) 1998-12-09 2002-11-30 Biocon Ltd
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CA2537958C (en) * 2003-09-11 2013-06-11 Sandoz Ag Process for the production of mycophenolate mofetil
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006012385A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2008000418A2 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Also Published As

Publication number Publication date
US5545637A (en) 1996-08-13
FI961169A (fi) 1996-03-13
WO1995007902A1 (en) 1995-03-23
HUT75119A (en) 1997-04-28
CN1131420A (zh) 1996-09-18
EP0724581A1 (en) 1996-08-07
SI9420052A (en) 1996-12-31
UA49797C2 (uk) 2002-10-15
NZ273801A (en) 1997-10-24
NO314727B1 (no) 2003-05-12
PL178522B1 (pl) 2000-05-31
CZ292423B6 (cs) 2003-09-17
KR100349772B1 (ko) 2002-12-28
CA2171836A1 (en) 1995-03-23
SI9420052B (sl) 2004-02-29
CN1060770C (zh) 2001-01-17
HK1012624A1 (en) 1999-08-06
HU9600652D0 (en) 1996-05-28
DE69414720T2 (de) 1999-04-08
JP3411038B2 (ja) 2003-05-26
EP0724581B1 (en) 1998-11-18
BR9407469A (pt) 1996-11-12
RU2132849C1 (ru) 1999-07-10
CZ78896A3 (en) 1996-10-16
LV11326A (lv) 1996-06-20
JPH09502721A (ja) 1997-03-18
PL313480A1 (en) 1996-07-08
ATE173475T1 (de) 1998-12-15
MXPA94007099A (es) 2004-01-23
FI119639B (fi) 2009-01-30
FI961169A0 (fi) 1996-03-13
US5543408A (en) 1996-08-06
RO118427B1 (ro) 2003-05-30
CA2171836C (en) 2006-11-14
ZA947088B (en) 1996-03-14
LT96028A (en) 1996-08-26
NO961075D0 (no) 1996-03-15
PH30685A (en) 1997-09-16
IL110970A (en) 1999-01-26
LT4052B (en) 1996-10-25
NO961075L (no) 1996-03-15
SG55006A1 (en) 1998-12-21
RO118075B1 (ro) 2003-01-30
IL110970A0 (en) 1994-11-28
AU677435B2 (en) 1997-04-24
TW370527B (en) 1999-09-21
HU217300B (hu) 1999-12-28
DK0724581T3 (da) 1999-08-02
ES2123831T3 (es) 1999-01-16
DE69414720D1 (de) 1998-12-24
AU7723894A (en) 1995-04-03

Similar Documents

Publication Publication Date Title
LV11326B (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
US9642853B2 (en) Stable pharmaceutical composition containing folates
US9301922B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
US20160143911A1 (en) Stable and water soluble pharmaceutical compositions comprising pemetrexed
ES2657944T3 (es) Sal estable de arginina de pemetrexed y composiciones que la comprenden
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
JPH0645551B2 (ja) インタ−ロイキン−2組成物
KR102413426B1 (ko) 나라트립탄을 포함하는 구강용해 필름 제형
UA59376C2 (uk) Стабілізована фармацевтична композиція на основі хінупристину та дальфопристину та спосіб її одержання
JPWO2006038526A1 (ja) イリノテカン酸付加塩
JP2001519390A (ja) 安定剤としてグリシンを含む製薬学的製剤
US20070014875A1 (en) Novel drug delivery system for proton pump inhibitors and process thereof
WO2024009319A1 (en) Liquid injectable compositions of trilaciclib
WO2024161316A1 (en) Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法
KR20060130933A (ko) 클로트리마졸 함유 직장 좌제 조성물